

# Alessandro A E Testori

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/8945256/alessandro-a-e-testori-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

156  
papers

20,795  
citations

53  
h-index

144  
g-index

170  
ext. papers

23,825  
ext. citations

7.2  
avg, IF

5.73  
L-index

#	Paper	IF	Citations
156	Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC).. <i>Annals of Surgical Oncology</i> , <b>2022</b> , 1	3.1	1
155	Real Life Clinical Management and Survival in Advanced Cutaneous Melanoma: The Italian Clinical National Melanoma Registry Experience. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 672797	5.3	2
154	Preoperative Ultrasound Assessment of Regional Lymph Nodes in Melanoma Patients Does not Provide Reliable Nodal Staging: Results From a Large Multicenter Trial. <i>Annals of Surgery</i> , <b>2021</b> , 273, 814-820	7.8	5
153	Adjuvant therapy with pegylated interferon-alfa2b vs observation in stage II B/C patients with ulcerated primary: Results of the European Organisation for Research and Treatment of Cancer 18081 randomised trial. <i>European Journal of Cancer</i> , <b>2020</b> , 133, 94-103	7.5	8
152	The EORTC-DeCOG nomogram adequately predicts outcomes of patients with sentinel node-positive melanoma without the need for completion lymph node dissection. <i>European Journal of Cancer</i> , <b>2020</b> , 134, 9-18	7.5	4
151	Prognosis of Patients With Stage III Melanoma According to American Joint Committee on Cancer Version 8: A Reassessment on the Basis of 3 Independent Stage III Melanoma Cohorts. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 2543-2551	2.2	13
150	Letter to the European Dermatology Forum, the European Association of Dermato-Oncology and the European Organization for Research and Treatment of Cancer on guidelines on basal cell carcinoma. <i>European Journal of Cancer</i> , <b>2020</b> , 140, 151-153	7.5	1
149	Adjuvant Therapy for Melanoma: Past, Current, and Future Developments. <i>Cancers</i> , <b>2020</b> , 12,	6.6	13
148	The Great Debate at "Melanoma Bridge", Naples, December 7th, 2019. <i>Journal of Translational Medicine</i> , <b>2020</b> , 18, 171	8.5	1
147	Adjuvant Treatment of Melanoma: Recent Developments and Future Perspectives. <i>American Journal of Clinical Dermatology</i> , <b>2019</b> , 20, 817-827	7.1	22
146	Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial. <i>European Journal of Cancer</i> , <b>2019</b> , 119, 1-10	7.5	79
145	Surgery for Metastatic Melanoma: an Evolving Concept. <i>Current Oncology Reports</i> , <b>2019</b> , 21, 98	6.3	5
144	Primary Melanoma: from History to Actual Debates. <i>Current Oncology Reports</i> , <b>2019</b> , 21, 112	6.3	5
143	Risk stratification of sentinel node-positive melanoma patients defines surgical management and adjuvant therapy treatment considerations. <i>European Journal of Cancer</i> , <b>2018</b> , 96, 25-33	7.5	50
142	Lymph node ratio as a prognostic factor in melanoma: results from European Organization for Research and Treatment of Cancer 18871, 18952, and 18991 studies. <i>Melanoma Research</i> , <b>2018</b> , 28, 222-229	3.29	3
141	MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , <b>2018</b> , 19, 916-929	21.7	83
140	Pregnancy and melanoma: a European-wide survey to assess current management and a critical literature overview. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2017</b> , 31, 65-69	4.6	12

139	Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2017</b> , 18, 393-403	21.7	69
138	Ipilimumab Adjuvant Therapy in Melanoma. <i>New England Journal of Medicine</i> , <b>2017</b> , 376, 399	59.2	7
137	The Impact of Smoking on Sentinel Node Metastasis of Primary Cutaneous Melanoma. <i>Annals of Surgical Oncology</i> , <b>2017</b> , 24, 2089-2094	3.1	18
136	Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. <i>New England Journal of Medicine</i> , <b>2017</b> , 376, 2211-2222	59.2	739
135	Preliminary data of VEGF-A and VEGFR-2 polymorphisms as predictive factors of radiological response and clinical outcome in iodine-refractory differentiated thyroid cancer treated with sorafenib. <i>Endocrine</i> , <b>2017</b> , 57, 539-543	4	6
134	Germline Polymorphisms of the VEGF Pathway Predict Recurrence in Nonadvanced Differentiated Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2017</b> , 102, 661-671	5.6	16
133	Multiple primary melanomas (MPMs) and criteria for genetic assessment: MultiMEL, a multicenter study of the Italian Melanoma Intergroup. <i>Journal of the American Academy of Dermatology</i> , <b>2016</b> , 74, 325-32	4.5	23
132	Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity. <i>European Journal of Cancer</i> , <b>2016</b> , 55, 111-21	7.5	70
131	Learning from mistakes: errors in approaches to melanoma and the urgent need for updated national guidelines. <i>International Journal of Dermatology</i> , <b>2016</b> , 55, 970-6	1.7	3
130	Treatment efficacy with electrochemotherapy: A multi-institutional prospective observational study on 376 patients with superficial tumors. <i>European Journal of Surgical Oncology</i> , <b>2016</b> , 42, 1914-1923	3.6	63
129	Unknown Primary Melanoma: Worldwide Survey on Clinical Management. <i>Dermatology</i> , <b>2016</b> , 232, 704-707	4.7	14
128	In Vivo Genetic Screens of Patient-Derived Tumors Revealed Unexpected Frailty of the Transformed Phenotype. <i>Cancer Discovery</i> , <b>2016</b> , 6, 650-63	24.4	45
127	Sun exposure and melanoma prognostic factors. <i>Oncology Letters</i> , <b>2016</b> , 11, 2706-2714	2.6	20
126	BCAM and LAMA5 Mediate the Recognition between Tumor Cells and the Endothelium in the Metastatic Spreading of KRAS-Mutant Colorectal Cancer. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 4923-4933	12.9	34
125	Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. <i>New England Journal of Medicine</i> , <b>2016</b> , 375, 1845-1855	59.2	870
124	Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline. <i>European Journal of Cancer</i> , <b>2015</b> , 51, 1989-2007	7.5	292
123	Diagnosis and treatment of dermatofibrosarcoma protuberans. European consensus-based interdisciplinary guideline. <i>European Journal of Cancer</i> , <b>2015</b> , 51, 2604-8	7.5	72
122	Report from the second MIB (Melanoma Independent Board) Conference, 27-28 October 2014. <i>Ecancermedicalscience</i> , <b>2015</b> , 9, 511	2.7	

121	Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2015</b> , 16, 522-30	21.7	842
120	Five-year survival rates for treatment-naïve patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 1191-6	2.2	334
119	Diagnosis and treatment of Merkel Cell Carcinoma. European consensus-based interdisciplinary guideline. <i>European Journal of Cancer</i> , <b>2015</b> , 51, 2396-403	7.5	170
118	EANM practice guidelines for lymphoscintigraphy and sentinel lymph node biopsy in melanoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2015</b> , 42, 1750-1766	8.8	76
117	Dacarbazine in combination with bevacizumab for the treatment of unresectable/metastatic melanoma: a phase II study. <i>Melanoma Research</i> , <b>2015</b> , 25, 239-45	3.3	17
116	Combined approach for the biomechanical characterization of skin lesions. <i>Annual International Conference of the IEEE Engineering in Medicine and Biology Society IEEE Engineering in Medicine and Biology Society Annual International Conference</i> , <b>2015</b> , 2015, 913-6	0.9	
115	Skin-directed electrochemotherapy: A prospective multi-institutional study on 394 patients with superficial tumors.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e20001-e20001	2.2	
114	Heat-shock proteins-based immunotherapy for advanced melanoma in the era of target therapies and immunomodulating agents. <i>Expert Opinion on Biological Therapy</i> , <b>2014</b> , 14, 955-67	5.4	20
113	Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2014</b> , 33, 30	12.8	76
112	Clinical experience with ipilimumab 3mg/kg: real-world efficacy and safety data from an expanded access programme cohort. <i>Journal of Translational Medicine</i> , <b>2014</b> , 12, 116	8.5	130
111	Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. <i>Lancet Oncology, The</i> , <b>2014</b> , 15, 323-32	21.7	753
110	Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma. <i>European Journal of Cancer</i> , <b>2014</b> , 50, 121-7	7.5	126
109	Maspin expression and melanoma progression: a matter of sub-cellular localization. <i>Modern Pathology</i> , <b>2014</b> , 27, 412-9	9.8	11
108	Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program. <i>Cancer Investigation</i> , <b>2014</b> , 32, 144-9	2.1	74
107	Treatment of metastatic melanoma with electrochemotherapy. <i>Journal of Surgical Oncology</i> , <b>2014</b> , 109, 301-7	2.8	37
106	The risk of developing a second primary cancer in melanoma patients: a comprehensive review of the literature and meta-analysis. <i>Journal of Dermatological Science</i> , <b>2014</b> , 75, 3-9	4.3	49
105	Final overall survival from a phase 3 trial of nab-paclitaxel versus dacarbazine (DTIC) in chemotherapy-naïve patients with metastatic melanoma.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 9045-9045	2.2	3
104	Ipilimumab versus placebo after complete resection of stage III melanoma: Initial efficacy and safety results from the EORTC 18071 phase III trial.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, LBA9008-LBA9008	2.2	13

103	Ipilimumab versus placebo after complete resection of stage III melanoma: Initial efficacy and safety results from the EORTC 18071 phase III trial.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, LBA9008-LBA9008	2.2	22
102	Electrochemotherapy: A treatment with specific intent in specific skin tumors Experience from the European Institute of Oncology, Milan.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, e20042-e20042	2.2	
101	Phase I-II study of the combination vemurafenib plus peg-interferon in advanced melanoma patients harboring the V600BRAF mutation.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, TPS9105-TPS9105	2.2	
100	Brain metastasis in melanoma patients: Associations with BRAF status and age.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, e20037-e20037	2.2	
99	Sentinel node biopsy in thin and thick melanoma. <i>Annals of Surgical Oncology</i> , <b>2013</b> , 20, 2780-6	3.1	58
98	Analysis of surrogate gene expression markers in peripheral blood of melanoma patients to predict treatment outcome of adjuvant pegylated interferon alpha 2b (EORTC 18991 side study). <i>Cancer Immunology, Immunotherapy</i> , <b>2013</b> , 62, 1223-33	7.4	5
97	Whole-body diffusion-weighted imaging: is it all we need for detecting metastases in melanoma patients?. <i>European Radiology</i> , <b>2013</b> , 23, 3466-76	8	29
96	Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 2413-20	2.2	163
95	Final results of phase III SYMMETRY study: randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients with advanced melanoma. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 1211-8	2.2	78
94	Pediatric melanoma: analysis of an international registry. <i>Cancer</i> , <b>2013</b> , 119, 4012-9	6.4	60
93	Follow-up of melanoma: a survey of Italian hospitals. <i>Dermatology</i> , <b>2013</b> , 226 Suppl 1, 32-8	4.4	9
92	Surgical management of suspicious melanocytic lesions in Italy. <i>Dermatology</i> , <b>2013</b> , 226 Suppl 1, 18-21	4.4	1
91	Management of small and intermediate congenital nevi: a nationwide survey in Italy. <i>Dermatology</i> , <b>2013</b> , 226 Suppl 1, 7-12	4.4	4
90	Diagnostic and therapeutic approaches in Italian hospitals: adjuvant and metastatic therapy in melanoma. <i>Dermatology</i> , <b>2013</b> , 226 Suppl 1, 22-7	4.4	4
89	Impact of mole mapping in the Italian health system. <i>Dermatology</i> , <b>2013</b> , 226 Suppl 1, 13-7	4.4	2
88	Clinical experience with ipilimumab 10mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2013</b> , 32, 82	12.8	16
87	Surgical treatment of melanoma: a survey of Italian hospitals. <i>Dermatology</i> , <b>2013</b> , 226 Suppl 1, 28-31	4.4	21
86	Diagnostic services for melanoma in Italy. <i>Dermatology</i> , <b>2013</b> , 226 Suppl 1, 3-6	4.4	2

85	Melanoma Task Force (META) Project in Italy: methodology. <i>Dermatology</i> , <b>2013</b> , 226 Suppl 1, 1-2	4.4	17
84	Sunny holidays before and after melanoma diagnosis are respectively associated with lower Breslow thickness and lower relapse rates in Italy. <i>PLoS ONE</i> , <b>2013</b> , 8, e78820	3.7	9
83	Lenvatinib combined with dacarbazine versus dacarbazine alone as first-line treatment in patients with stage IV melanoma.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 9027-9027	2.2	3
82	A phase III trial of nab-paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma: A subanalysis based on BRAF status.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 9030-9030	3.3	5
81	Correlation between efficacy and toxicity in pts with pretreated advanced melanoma treated within the Italian cohort of the ipilimumab expanded access programme (EAP).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 9065-9065	2.2	7
80	Efficacy and safety data from elderly patients with pretreated advanced melanoma in the Italian cohort of ipilimumab expanded access programme (EAP).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 9548-9548	2.2	7
79	Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy. <i>Cancer Immunology, Immunotherapy</i> , <b>2012</b> , 61, 41-8	7.4	104
78	Sarcoma spreads primarily through the vascular system: are there biomarkers associated with vascular spread?. <i>Clinical and Experimental Metastasis</i> , <b>2012</b> , 29, 757-73	4.7	21
77	Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. <i>European Journal of Cancer</i> , <b>2012</b> , 48, 218-25	7.5	146
76	Recurrence and prognostic factors in patients with aggressive fibromatosis. The role of radical surgery and its limitations. <i>World Journal of Surgical Oncology</i> , <b>2012</b> , 10, 184	3.4	29
75	Alternatives for the treatment of local advanced disease: electrochemotherapy, limb perfusion, limb infusion, intralesional IL2. What is the role?. <i>Dermatologic Therapy</i> , <b>2012</b> , 25, 443-51	2.2	8
74	EORTC Melanoma Group achievements. <i>European Journal of Cancer, Supplement</i> , <b>2012</b> , 10, 112-119	1.6	
73	Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. <i>Lancet Oncology, The</i> , <b>2012</b> , 13, 879-86	21.7	232
72	The cost of unresectable stage III or stage IV melanoma in Italy. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2012</b> , 31, 91	12.8	20
71	Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3810-8	2.2	204
70	Utility of electrochemotherapy in melanoma treatment. <i>Current Opinion in Oncology</i> , <b>2012</b> , 24, 155-61	4.2	28
69	Ipilimumab targeting CD28-CTLA-4 axis: new hope in the treatment of melanoma. <i>Current Topics in Medicinal Chemistry</i> , <b>2012</b> , 12, 61-6	3	5
68	Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAFV600E-mutated melanoma.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 8502-8502	2.2	65

67	Phase II multicenter trial of ipilimumab combined with fotemustine in patients with metastatic melanoma: The Italian Network for Tumor Biotherapy (NIBIT)-M1 trial.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 8513-8513	2.2	5
66	The NIBIT-M1 trial: Activity of ipilimumab plus fotemustine in patients with melanoma and brain metastases.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 8529-8529	2.2	5
65	Randomized phase III trial of intravenous (IV) versus hepatic intra-arterial (HIA) fotemustine in patients with liver metastases from uveal melanoma: Final results of the EORTC 18021 study.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 8532-8532	2.2	5
64	Long-term outcome after complete resection and adjuvant immunotherapy for distant melanoma metastases.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 8534-8534	2.2	1
63	Surgery in stage IV melanoma patients: Results from a single institution.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, e19035-e19035	2.2	2
62	Vulvar melanoma: A monocentric retrospective study on 29 cases.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, e19036-e19036	2.2	
61	Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. <i>New England Journal of Medicine</i> , <b>2011</b> , 364, 2517-26	59.2	3396
60	The immunological era in melanoma treatment: new challenges for heat shock protein-based vaccine in the advanced disease. <i>Expert Opinion on Biological Therapy</i> , <b>2011</b> , 11, 1395-407	5.4	7
59	Improved survival with vemurafenib in melanoma with BRAF V600E mutation. <i>New England Journal of Medicine</i> , <b>2011</b> , 364, 2507-16	59.2	5851
58	Diagnostic and therapeutic imaging for cancer: therapeutic considerations and future directions. <i>Journal of Surgical Oncology</i> , <b>2011</b> , 103, 587-601	2.8	16
57	Treatment of melanoma metastases in a limb by isolated limb perfusion and isolated limb infusion. <i>Journal of Surgical Oncology</i> , <b>2011</b> , 104, 397-404	2.8	29
56	Local and intralesional therapy of in-transit melanoma metastases. <i>Journal of Surgical Oncology</i> , <b>2011</b> , 104, 391-6	2.8	65
55	Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteria. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 2206-14	2.2	164
54	Phase III trial comparing adjuvant treatment with pegylated interferon Alfa-2b versus observation: prognostic significance of autoantibodies--EORTC 18991. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 2460-6	2.2	57
53	Reply to F. Janku et al. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, e17-e18	2.2	7
52	Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 1780-7	2.2	52
51	Pelvic sentinel lymph node biopsy in melanoma patients: is it worthwhile?. <i>Melanoma Research</i> , <b>2010</b> , 20, 133-7	3.3	7
50	Serum concentrations of pegylated interferon alpha-2b in patients with resected stage III melanoma receiving adjuvant pegylated interferon alpha-2b in a randomized phase III trial (EORTC 18991). <i>Cancer Chemotherapy and Pharmacology</i> , <b>2010</b> , 65, 671-7	3.5	14

49	Anti-CTLA-4 antibody adjuvant therapy in melanoma. <i>Seminars in Oncology</i> , <b>2010</b> , 37, 455-9	5.5	33
48	Electrochemotherapy for cutaneous and subcutaneous tumor lesions: a novel therapeutic approach. <i>Dermatologic Therapy</i> , <b>2010</b> , 23, 651-61	2.2	100
47	Radio-guided ultrasound lymph node localization: feasibility of a new technique for localizing and excising nonpalpable lymph nodes ultrasound suspicious for melanoma metastases. <i>Melanoma Research</i> , <b>2010</b> , 20, 197-202	3.3	9
46	Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 2916-23	2.2	88
45	HSPPC-96 vaccine in metastatic melanoma patients: from the state of the art to a possible future. <i>Expert Review of Vaccines</i> , <b>2009</b> , 8, 1513-26	5.2	13
44	Oncophage <sup>®</sup> (vitespen <sup>®</sup> ) - Heat shock protein peptide complex 96-based vaccines in melanoma: How far we are, how far we can get?. <i>Hum Vaccin</i> , <b>2009</b> , 5, 727-737		11
43	EANM-EORTC general recommendations for sentinel node diagnostics in melanoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2009</b> , 36, 1713-42	8.8	140
42	Clinical considerations on sentinel node biopsy in melanoma from an Italian multicentric study on 1,313 patients (SOLISM-IMI). <i>Annals of Surgical Oncology</i> , <b>2009</b> , 16, 2018-27	3.1	108
41	Desmoid tumors of the anterior abdominal wall: results from a monocentric surgical experience and review of the literature. <i>Annals of Surgical Oncology</i> , <b>2009</b> , 16, 1642-9	3.1	43
40	Vitamin D and skin cancer: a meta-analysis. <i>European Journal of Cancer</i> , <b>2009</b> , 45, 634-41	7.5	95
39	Circulating melanoma cells and distant metastasis-free survival in stage III melanoma patients with or without adjuvant interferon treatment (EORTC 18991 side study). <i>European Journal of Cancer</i> , <b>2009</b> , 45, 3189-97	7.5	37
38	Clinical genetic testing for familial melanoma in Italy: a cooperative study. <i>Journal of the American Academy of Dermatology</i> , <b>2009</b> , 61, 775-82	4.5	39
37	Cutaneous melanoma in the elderly. <i>Melanoma Research</i> , <b>2009</b> , 19, 125-34	3.3	18
36	Oncophage: step to the future for vaccine therapy in melanoma. <i>Expert Opinion on Biological Therapy</i> , <b>2008</b> , 8, 1973-84	5.4	14
35	Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. <i>Lancet, The</i> , <b>2008</b> , 372, 117-126	4.0	496
34	Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 955-62	2.2	210
33	Genomic rearrangements of the CDKN2A locus are infrequent in Italian malignant melanoma families without evidence of CDKN2A/CDK4 point mutations. <i>Melanoma Research</i> , <b>2008</b> , 18, 431-7	3.3	7
32	Modification of lymphoscintigraphic sentinel node identification before and after excisional biopsy of primary cutaneous melanoma. <i>Melanoma Research</i> , <b>2008</b> , 18, 373-7	3.3	8



31	Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion. <i>Cancer</i> , <b>2008</b> , 112, 982-94	6.4	97
30	Dendritic cell sarcoma: an analytic overview of the literature and presentation of original five cases. <i>Critical Reviews in Oncology/Hematology</i> , <b>2008</b> , 65, 1-7	7	76
29	Anti-CTLA4 monoclonal antibody Ipilimumab in the treatment of metastatic melanoma: recent findings. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , <b>2008</b> , 3, 105-13	2.6	22
28	Long-term protective effect of mature DC-LAMP+ dendritic cell accumulation in sentinel lymph nodes containing micrometastatic melanoma. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 3825-30	12.9	59
27	Cutaneous melanoma: digital dermoscopy-essential tool for positive diagnosis. <i>Journal of Cellular and Molecular Medicine</i> , <b>2006</b> , 10, 991-4	5.6	7
26	Primary and recurrent retroperitoneal soft tissue sarcoma: prognostic factors affecting survival. <i>Journal of Surgical Oncology</i> , <b>2006</b> , 93, 456-63	2.8	17
25	Mitf regulation of Dia1 controls melanoma proliferation and invasiveness. <i>Genes and Development</i> , <b>2006</b> , 20, 3426-39	12.6	403
24	The impact of lymphoscintigraphy technique on the outcome of sentinel node biopsy in 1,313 patients with cutaneous melanoma: an Italian Multicentric Study (SOLISM-IMI). <i>Journal of Nuclear Medicine</i> , <b>2006</b> , 47, 234-41	8.9	31
23	Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. <i>Lancet, The</i> , <b>2005</b> , 366, 1189-96	40	265
22	Update: current management issues in malignant melanoma. <i>Melanoma Research</i> , <b>2005</b> , 15, 319-24	3.3	13
21	The role of ultrasound of sentinel nodes in the pre- and post-operative evaluation of stage I melanoma patients. <i>Melanoma Research</i> , <b>2005</b> , 15, 191-8	3.3	31
20	Pulsed dose-rate perioperative interstitial brachytherapy for soft tissue sarcomas of the extremities and skeletal muscles of the trunk. <i>Annals of Surgical Oncology</i> , <b>2005</b> , 12, 935-42	3.1	17
19	Heat shock proteins and their use as anticancer vaccines. <i>Clinical Cancer Research</i> , <b>2004</b> , 10, 8142-6	12.9	56
18	Heat shock proteins: biological functions and clinical application as personalized vaccines for human cancer. <i>Cancer Immunology, Immunotherapy</i> , <b>2004</b> , 53, 227-33	7.4	108
17	Surgical techniques of melanoma and sentinel node biopsy. <i>Seminars in Oncology</i> , <b>2002</b> , 29, 328-35	5.5	9
16	Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. <i>Journal of Clinical Oncology</i> , <b>2002</b> , 20, 4169-80	2.2	326
15	Epiluminescence microscopy features of melanoma in relation to tumor thickness. Current concepts and clinical examples. <i>Dermatologic Clinics</i> , <b>2001</b> , 19, 285-97	4.2	4
14	Sentinel lymph node biopsy in cutaneous melanoma: the WHO Melanoma Program experience. <i>Annals of Surgical Oncology</i> , <b>2000</b> , 7, 469-74	3.1	281

13	Sentinel node localization in cutaneous melanoma: lymphoscintigraphy with colloids and antibody fragments versus blue dye mapping. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>1998</b> , 25, 1489-94	8.8	33
12	Coming of age in culture. <i>Experimental Gerontology</i> , <b>1996</b> , 31, 7-12	4.5	36
11	The helix-loop-helix protein Id-1 and a retinoblastoma protein binding mutant of SV40 T antigen synergize to reactivate DNA synthesis in senescent human fibroblasts. <i>Genesis</i> , <b>1996</b> , 18, 161-72		64
10	The helix-loop-helix protein Id-1 and a retinoblastoma protein binding mutant of SV40 T antigen synergize to reactivate DNA synthesis in senescent human fibroblasts <b>1996</b> , 18, 161		1
9	Brain and testis selective expression of the glutathione S-transferase Yb3 subunit is governed by tandem direct repeat octamer motifs in the 5Rflanking region of its gene. <i>Molecular Brain Research</i> , <b>1995</b> , 28, 37-46		5
8	Acral lentiginous melanoma. A histological type without prognostic significance. <i>The Journal of Dermatologic Surgery and Oncology</i> , <b>1994</b> , 20, 817-22		41
7	Direct cloning of unmodified PCR products by exploiting an engineered restriction site. <i>Gene</i> , <b>1994</b> , 143, 151-2	3.8	13
6	Mucinous Carcinoma of the Breast. <i>American Journal of Surgical Pathology</i> , <b>1994</b> , 18, 702-711	6.7	86
5	Argyrophilia and granin (chromogranin/secretogranin) expression in female breast carcinomas. Their relationship to survival and other disease parameters. <i>American Journal of Surgical Pathology</i> , <b>1992</b> , 16, 561-76	6.7	47
4	In vivo spectrophotometric evaluation of neoplastic and non-neoplastic skin pigmented lesions--I. Reflectance measurements. <i>Photochemistry and Photobiology</i> , <b>1991</b> , 53, 77-84	3.6	68
3	Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors. <i>International Journal of Cancer</i> , <b>1991</b> , 49, 44-9	7.5	222
2	Comparison of long-term survival of 1986 consecutive patients with breast cancer treated at the National Cancer Institute of Milano, Italy (1971 to 1972 and 1977 to 1978). <i>Cancer</i> , <b>1991</b> , 68, 427-34	6.4	10
1	Long-Term Survival and Prognostic Factors for 2170 Breast Cancer Patients Treated at Two Cancer Centers: (Milan and Houston). <i>Tumori</i> , <b>1989</b> , 75, 123-131	1.7	8